Compare Crispr Therapeutics AG (CRSP) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Solaredge Technologies Inc — how do they compare? Crispr Therapeutics AG trades at $50.61 (market cap $4.97B), while Solaredge Technologies Inc trades at $53.62 (market cap $3.38B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Solaredge Technologies Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | SEDG | |
|---|---|---|
Market Cap | $4.97B | $3.38B |
Sector | Health | Technology |
52-Week High | $76.78 | $78.51 |
52-Week Low | $44.34 | $24.42 |
Enterprise Value | $3.32B | $3.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
SolarEdge Technologies (SEDG) trades at $52.13, down 5.53% amid bearish technical signals and mixed fundamentals. The stock shows negative profitability with a -28.56% net margin and -72.5% ROE, though recent quarters saw earnings beats. Revenue declined from $3.1B in 2022 to $1.18B in 2025, reflecting solar market challenges. Analyst sentiment is cautious with a $35.56 consensus target below current price, while technical indicators show bearish momentum with key support at $49.
SEDG faces significant headwinds with persistent losses and declining revenue, though operational cash flow turned positive in 2025. Investment opportunity exists if solar demand recovers, but risks include intense competition, policy uncertainty, and high debt levels. The stock remains speculative with substantial downside risk to analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
